These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37414222)

  • 41. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactions between nanoparticles and pathological changes of vascular in Alzheimer's disease.
    Lei T; Yang Z; Li H; Qin M; Gao H
    Adv Drug Deliv Rev; 2024 Apr; 207():115219. PubMed ID: 38401847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease.
    Sharma A; Angnes L; Sattarahmady N; Negahdary M; Heli H
    Biosensors (Basel); 2023 Jul; 13(7):. PubMed ID: 37504140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review.
    Ahmad SS; Khan S; Kamal MA; Wasi U
    CNS Neurol Disord Drug Targets; 2019; 18(9):657-667. PubMed ID: 31608840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanotechnology and Alzheimer's disease: what has been done and what to do.
    Ruozi B; Belletti D; Pederzoli F; Veratti P; Forni F; Vandelli MA; Tosi G
    Curr Med Chem; 2014; 21(36):4169-85. PubMed ID: 25039777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Potential biomarkers of early diagnosis of Alzheimer's disease].
    Bogolepova AN; Makhnovich EV; Kovalenko EA; Osinovskaya NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(9):7-14. PubMed ID: 36168682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.
    Amiri H; Saeidi K; Borhani P; Manafirad A; Ghavami M; Zerbi V
    ACS Chem Neurosci; 2013 Nov; 4(11):1417-29. PubMed ID: 24024702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers.
    Kim K; Lee CH; Park CB
    Chem Soc Rev; 2020 Aug; 49(15):5446-5472. PubMed ID: 32627779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform.
    Kolaj I; Imindu Liyanage S; Weaver DF
    Neurochem Int; 2018 Nov; 120():99-111. PubMed ID: 30098379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topographical Overlapping of the Amyloid-β and Tau Pathologies in the Default Mode Network Predicts Alzheimer's Disease with Higher Specificity.
    Hojjati SH; Feiz F; Ozoria S; Razlighi QR;
    J Alzheimers Dis; 2021; 83(1):407-421. PubMed ID: 34219729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease.
    Buchanan H; Mackay M; Palmer K; Tothová K; Katsur M; Platt B; Koss DJ
    Mol Neurobiol; 2020 Aug; 57(8):3258-3272. PubMed ID: 32514860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
    Tarawneh R; Holtzman DM
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease.
    Xu Y; Jiang H; Zhu B; Cao M; Feng T; Sun Z; Du G; Zhao Z
    CNS Neurosci Ther; 2023 Aug; 29(8):2060-2073. PubMed ID: 37144603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
    Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
    Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Oxidative stress and Alzheimer's disease].
    Liu XJ; Yang W; Qi JS
    Sheng Li Xue Bao; 2012 Feb; 64(1):87-95. PubMed ID: 22348966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Ossenkoppele R; van der Kant R; Hansson O
    Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanotechnology for Alzheimer Disease.
    Leszek J; Md Ashraf G; Tse WH; Zhang J; Gasiorowski K; Avila-Rodriguez MF; Tarasov VV; Barreto GE; Klochkov SG; Bachurin SO; Aliev G
    Curr Alzheimer Res; 2017; 14(11):1182-1189. PubMed ID: 28164767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions.
    Ma C; Hong F; Yang S
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.